view4D pharma plc

4d pharma reveals 'phenomenal results' from early stage cancer trial

4d pharma plc's (LON:DDDD) Duncan Peyton talks to Proactive London following the positive results of its clinical results in the first part of a trial on very poorly patients battling cancer.

The trial of its live biotherapeutic in combination with an established cancer drug called a checkpoint inhibitor resulted in five people, or 42% of the group, experiencing a clinically meaningful benefit from the two drugs.

Peyton explains how this is the first time live biotheroputics have been used in this way and without any side effects.

Quick facts: 4D pharma plc

Price: 158 GBX

Market: LSE
Market Cap: £207.6 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of 4D pharma plc named herein, including the promotion by the Company of 4D pharma plc in any Content on the Site, the Company receives from said...


Market Report: FTSE lacks direction as investors await next big market mover

The London bourse is slightly lower this Wednesday with US data pointing towards a potentially painful recession. More doom for the tourism industry following the news Princess Cruises (LON:CLL) said it would cancel early 2021 cruises on two ships due to the COVID-19 pandemic...

on 26/8/20

2 min read